Enclomiphene vs clomiphene vs TRT: what the trials measured

Reviewed 21 sourcesPublished by PepVault

Enclomiphene, clomiphene and testosterone side by side: the LH, FSH, testosterone and sperm numbers from their trials, and what was never measured.

A man in a black sleeveless top doing a pull-up on an outdoor bar
Last reviewed
Sources
21
Questions
7
Compounds
2

The short answer

All three raise testosterone, by two routes. TRT supplies testosterone itself, which switches off your own LH and FSH and, with them, sperm production. Clomiphene and enclomiphene block estrogen's brake in the brain, so LH, FSH and your own testosterone rise and sperm is mostly kept. TRT is FDA-approved for diagnosed hypogonadism, clomiphene only for women, enclomiphene for nothing.

Every number checked at its primary source · · 21 sources · How we research

Evidence: Testosterone: large randomized trials of symptoms and heart safety. Enclomiphene: randomized phase 2 and 3 trials of hormone levels and sperm. Clomiphene in men: small randomized trials and observational studies.

A man in a black sleeveless top doing a pull-up on an outdoor bar

How do enclomiphene, clomiphene and TRT differ?

They push the same chain from opposite ends. The brain's pituitary sends LH (luteinizing hormone), which tells the testes to make testosterone, and FSH (follicle-stimulating hormone), which with that testosterone drives sperm production. When testosterone and the estrogen made from it run high, the brain turns LH and FSH down.

TRT (testosterone replacement therapy) adds testosterone from outside, so the brain reads plenty and turns LH and FSH down14. Clomiphene and enclomiphene are SERMs (selective estrogen receptor modulators): pills that block the brain's estrogen sensor, so it reads too little and turns LH and FSH up, and the testes make more of their own testosterone11. Clomiphene is a mix of two forms of one molecule, enclomiphene and zuclomiphene13.

Side by sideTRT (testosterone)ClomipheneEnclomiphene
What it isTestosterone itself, as a gel, an injection and other forms14A pill: enclomiphene plus 30 to 50% zuclomiphene13A pill: the trans form of clomiphene alone13
Your own LH and FSHFall114Rise8Rise1
TestosteroneRises1Rises811Rises111
SpermCan be suppressed1415Concentration up in infertile men10Mostly kept47
US approvalMen with hypogonadism from a known cause14Ovulation problems in women; off-label in men13None: FDA letter 2015, EU refusal 20181819

PepVault's bloodwork log records total testosterone, LH, FSH, estradiol and hematocrit from each panel, and shows what moved since the last one. Log it in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's bloodwork log records total testosterone, LH, FSH, estradiol and hematocrit from each panel, and shows what moved since the last one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did the head-to-head trial of enclomiphene and testosterone gel find?

One trial put all the comparisons in one place. ZA-203 randomized 124 men with secondary hypogonadism (low testosterone with low or normal LH) and morning testosterone under 250 ng/dL to placebo, testosterone gel (Testim), or enclomiphene at 12.5 or 25 mg a day, for 3 months12. The registry's results, as the average change from the start:

After 3 months1PlaceboTestosterone gelEnclomiphene 12.5 mgEnclomiphene 25 mg
Total testosterone−16.9 ng/dL+253.7 ng/dL+258.5 ng/dL+197.3 ng/dL
LH−0.1 IU/L−2.4 IU/L+4.8 IU/L+6.9 IU/L
FSH−0.2 IU/L−4.4 IU/L+5.1 IU/L+7.4 IU/L
Men with a sperm-count drop reported as a side effect0 of 288 of 330 of 270 of 33

Testosterone rose by about the same amount on the gel and the pill. The difference is in the next two rows: the gel lowered LH and FSH, enclomiphene raised them. An earlier phase 2 trial in 48 men found the same split at day 42: 604 ng/dL on 25 mg against 500 ng/dL on gel, not a significant difference, with LH suppressed on the gel and pushed above the normal range on enclomiphene3.

IU/L and mIU/mL are the same unit, so these LH and FSH changes read directly against a lab report. The doses are the trials' arms, not a protocol.

What happened to sperm on each one?

Sperm is where the routes part. In a small 6-month trial of 12 men who had used testosterone gel before, enclomiphene raised sperm counts in 7 of 7 men at 3 months, with counts in the 75 to 334 million/mL range, while the gel took none of 5 men above 20 million/mL4. In two 16-week phase 3 trials, ZA-304 and ZA-305, enclomiphene kept sperm concentration in the normal range while the gel group showed a marked fall7.

Enclomiphene is not sperm-neutral for everyone. In the placebo-controlled ZA-301 and ZA-302 trials, 14.2% of men on enclomiphene saw sperm concentration fall by half or more, against 2.6% and 4.3% on placebo56.

For testosterone, the clearest number comes from a contraception trial. Of 271 healthy fertile men given 200 mg of testosterone enanthate by injection each week, 157 had no sperm in three samples in a row, a cumulative 65% by 6 months. After the shots stopped, sperm took a median 3.7 months to reach 20 million/mL15. The AndroGel label says large doses can suppress sperm production through the brain's FSH signal14.

Clomiphene, in a 2023 meta-analysis of 15 studies in 566 infertile men, raised sperm concentration by an average 8.38 million/mL and motility by 8.14 percentage points, with sperm shape unchanged; the pooled numbers compare the same men before and during treatment, with no placebo group10.

What did the clomiphene trials in men measure?

Hormones and body composition, in small randomized trials of men with obesity. In a double-blind crossover trial, 21 men with prediabetes or type 2 diabetes on metformin took 25 mg of clomiphene a day or placebo for 3 months each8:

Before and after 3 months8Clomiphene 25 mgPlacebo
Total testosterone303 → 599 ng/dL287 → 309 ng/dL
LH3.83 → 8.53 IU/L3.51 → 3.63 IU/L
FSH4.84 → 10.15 IU/L4.61 → 5.39 IU/L

Fasting glucose and insulin also fell on clomiphene8. In a second trial, 78 men with a BMI over 30 and testosterone at or under 300 ng/dL took 50 mg or placebo for 12 weeks: total and free testosterone, estradiol, LH and FSH rose, lean and muscle mass rose, weaker erections improved, and HDL cholesterol fell9.

Pooled across randomized trials of clomiphene and enclomiphene together, total testosterone came out 273.76 ng/dL above placebo, LH 4.66 IU/L and FSH 4.59 IU/L higher; against testosterone gel, testosterone did not differ, while LH and FSH were higher11.

Is enclomiphene better than clomiphene?

It may be gentler, but no randomized trial has compared them. The reason to expect a difference is the other half of clomiphene. The label says some data suggest zuclomiphene has more estrogen-like activity than enclomiphene, that it has a longer half-life, and that it was still detectable in the blood more than a month after a single dose13.

The direct comparisons are two chart reviews. One followed 66 men at one US center who took clomiphene and later switched to enclomiphene. Median testosterone rose 166 ng/dL on enclomiphene and 98 ng/dL on clomiphene, a gap that was not significant (P = 0.20). Estradiol fell 5.92 pg/mL on enclomiphene and rose 17.50 pg/mL on clomiphene, and side effects were less likely on enclomiphene (odds ratio 0.18), lower libido, less energy and mood changes in particular12. Because every man took clomiphene first, time and order may explain part of it. The other, of 78 men treated for infertility or low testosterone in Miami, found both raised testosterone, while only enclomiphene raised LH, FSH and total motile sperm count significantly21.

Commonly reported: on clomiphene, irritability, mood swings and, less often, blurred vision or spots; on enclomiphene, more energy and libido within a few weeks with fewer mood complaints; on TRT, steadier energy and libido, and smaller, softer testes over months.

What did the TRT trials measure that the pill trials did not?

How men felt, and what happened to their hearts. The enclomiphene program measured blood levels and sperm. The EU regulator refused it in 2018 because its studies did not look at symptoms such as bone strength, weight gain, impotence and libido, and named a risk of blood clots19. The FDA's 2015 letter, as its maker reported it, found the phase 3 design no longer adequate to show clinical benefit and asked for more phase 3 work18.

Testosterone has those trials. In 790 men aged 65 and over, a year of gel raised sexual activity, desire and erectile function and slightly improved mood, with no gain in vitality17. TRAVERSE followed 5,246 men aged 45 to 80 with heart disease or high risk for about 33 months: major heart events occurred in 7.0% on gel and 7.3% on placebo, while atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent on testosterone16.

The AndroGel label, revised in July 2025, adds measured costs: blood pressure up 1.9/1.3 mm Hg after 16 weeks, a rise in hematocrit (the share of blood that is red cells) to check before and during treatment, and a boxed warning about children exposed to the gel on skin14. The clomiphene label warns of visual symptoms, blurring, spots or flashes, more likely with higher doses and longer use13.

Which one fits which situation?

Two questions sort them: can the pituitary still answer, and does fertility matter now? The Endocrine Society diagnoses low testosterone only with symptoms and consistently low morning tests, repeated, and advises against starting testosterone in men planning fertility in the near term20.

  • Fertility matters, pituitary works, LH low or normal: the group every enclomiphene trial enrolled, and the one clomiphene is used for off-label156.
  • Testes themselves not working (high LH): no SERM trial here enrolled these men, since the trials capped LH at entry56. With the brain already signalling hard, a SERM has little left to push; testosterone is the approved treatment14.
  • Symptom relief proven in trials, fertility not a goal now: only testosterone has randomized trials of symptoms and heart outcomes1617.

Each compound has its own page, pepvault.app/peptides/enclomiphene and pepvault.app/peptides/clomiphene, and the two are compared at pepvault.app/peptides/compare/clomiphene-vs-enclomiphene. The main trials have study pages, such as pepvault.app/research/enclomiphene-za-304-and-za-305-2016 and pepvault.app/research/enclomiphene-saffati-2024; SERM is in the glossary at pepvault.app/glossary/serm. For the wider question, lifestyle included, the next guide is on raising testosterone.

In PepVault you can set a reminder for a daily pill or a testosterone shot, and log each dose, so the weeks line up with your next blood test. Set reminders in PepVault

When to get help On clomiphene or enclomiphene, blurred vision, spots or flashes, or a swollen, painful leg or sudden shortness of breath, are reasons to call a doctor the same day1319.

Track it in the app

Sources

  1. ZA-203: Normalization of morning testosterone levels in men with secondary hypogonadism (enclomiphene 12.5 or 25 mg vs Testim vs placebo). ClinicalTrials.gov NCT01270841 (Repros Therapeutics), results. clinicaltrials.gov
  2. Wiehle RD et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014. PubMed 25044085
  3. Wiehle R et al. Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. 2013. PubMed 23875626
  4. Kaminetsky J et al. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013. PubMed 23530575
  5. ZA-301: Phase III study to evaluate morning testosterone normalization in men with secondary hypogonadism. ClinicalTrials.gov NCT01532414 (Repros Therapeutics), results. clinicaltrials.gov
  6. ZA-302: Phase III study to evaluate morning testosterone normalization in overweight men with secondary hypogonadism. ClinicalTrials.gov NCT01739595 (Repros Therapeutics), results. clinicaltrials.gov
  7. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016. PubMed 26496621
  8. Pelusi C et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: a randomized, double-blind, placebo-controlled study. PLoS One. 2017. PubMed 28886024
  9. Soares AH et al. Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond). 2018. PubMed 29777228
  10. Huijben M et al. Clomiphene citrate for male infertility: a systematic review and meta-analysis. Andrology. 2023. PubMed 36680549
  11. Hohl A et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025. PubMed 41066380
  12. Saffati G et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol. 2024. PubMed 39434750
  13. Clomid (clomiphene citrate tablets) prescribing information, Cosette Pharmaceuticals. DailyMed, published Feb 3, 2025. dailymed.nlm.nih.gov
  14. AndroGel 1.62% (testosterone gel) prescribing information, revised 07/2025. DailyMed, published Nov 17, 2025. dailymed.nlm.nih.gov
  15. World Health Organization Task Force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990. PubMed 1977002
  16. Lincoff AM et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023. PubMed 37326322
  17. Snyder PJ et al. Effects of testosterone treatment in older men. N Engl J Med. 2016. PubMed 26886521
  18. Repros Therapeutics. Repros receives complete response letter from FDA for enclomiphene. Form 8-K press release, Dec 1, 2015. sec.gov
  19. European Medicines Agency. EnCyzix (enclomiphene): refusal of the marketing authorisation, 2018. ema.europa.eu
  20. Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. PubMed 29562364
  21. Thomas J et al. Efficacy of clomiphene citrate versus enclomiphene citrate for male infertility treatment: a retrospective study. Cureus. 2023. PubMed 37546076

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo